Nutra Pharma announced today that DNAA, Inc will serve as their Distributor in Panama for its Nyloxin-branded pain relievers.
Coral Springs, FL. – October 14, 2011 - Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain announced today that it has selected DNAA, Inc. to serve as the exclusive distributor in Panama for its Nyloxin-branded pain relievers.
“Nutra Pharma is dedicated to a comprehensive, international roll-out of our products. To do so, we are establishing the framework for international distribution of our pain relievers,” commented Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. "DNAA has already begun the registration process for our Nyloxin products in Panama and will begin an aggressive marketing campaign throughout Central America once they have received regulatory clearance,” he added.
Nyloxin™ is an over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. Nyloxin™ is currently available in the United States as an oral spray for treating back pain, neck aches, headaches, joint pain, migraines, and neuralgia, and as a topical gel for treating joint pain, neck pain, arthritis pain, and pain from repetitive stress. In addition to its everyday strength formulation, Nyloxin™ is also offered in an extra strength formula for more advanced, Stage 3, chronic pain.
"We are excited to be working with Nutra Pharma," stated Nicolas Ardito Barletta, President of DNAA, Inc. "Nyloxin represents an entirely new concept in the treatment of chronic pain and inflammation. We believe that this will create a great opportunity in Panama and the rest of Central America," he concluded.
Previously, Nutra Pharma announced agreements with distributors in Mexico, Colombia, Venezuela, Lebanon and Jordan. The drug registration process for both Cobroxin® and Nyloxin™ are currently being pursued in more than 20 countries.
About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets several drug products for sale for the treatment of pain under the brands Cobroxin® and Nyloxin™. For additional information about Nutra Pharma, visit: http://www.NutraPharma.com
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The distribution of Nyloxin™ into Panama through DNAA, Inc. should not be construed as an indication in any way whatsoever of the future value of the Company’s common stock or its financial value. Additionally, this distribution agreement does not ensure that the Company will have material sales in Jordan. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.